18 June 2018
New drugs and treatments development requires experiments on animals and humans. However, many problems can be solved just by studying the samples of human tissues outside the human body. To this end, Russia is establishing a nationwide network of biobanks.
According to Vitaly Prutsky, the head of National BioService (NBS), this project provides for developing the All-Russian network of biobanks. They will collaborate with clinical centers. NBS will provide materials to diagnostic and pharmaceutical organizations and conduct independent studies.
“For example, N.F. Gamaleya Scientific Research Institute of Epidemiology and Microbiology in Moscow is developing antibodies against the Ebola virus,” said Vitaly Prutsky. “This involves a risk of side effects. For example, what if a person is treated for Ebola but suddenly goes blind? So, we are helping Gamaleya Institute to study the reaction of antibodies to a wide variety of tissues.”
NBS biobanking and bioservice are sought after by pharmaceutical and diagnostic companies not only from Russia but also other countries.
“Our organization is integrated into the international process of innovative medical research,” said Anton Vasilyev, Chief Investment Director of RVC InfraFund, the management organization of BioFund.
He added that there are about 200 large biobanks outside Russia. But leading international pharmaceutical companies are willing to use the services of Russian NBS.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024